Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2005-12-27
2005-12-27
Leffers, Gerry (Department: 1636)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S069700, C435S252300, C435S471000, C435S252330, C435S069600, C536S023100, C536S023400, C530S387100
Reexamination Certificate
active
06979556
ABSTRACT:
The present invention provides methods and compositions for improved expression and production of recombinant antibodies in prokaryotic expression systems. Particularly contemplated are prokaryotic expression and production of full length aglycosylated antibodies. The antibody products of the invention can be used in various aspects of biological research, diagnosis and medical treatment.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5264365 (1993-11-01), Georgiou et al.
patent: 5500362 (1996-03-01), Robinson et al.
patent: 5508192 (1996-04-01), Georgiou et al.
patent: 5585097 (1996-12-01), Bolt et al.
patent: 5639635 (1997-06-01), Joly et al.
patent: 5648237 (1997-07-01), Carter
patent: 5747662 (1998-05-01), Simmons et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5840523 (1998-11-01), Simmons et al.
patent: 6008023 (1999-12-01), Opper et al.
patent: 6027888 (2000-02-01), Georgiou et al.
patent: 6083715 (2000-07-01), Georgiou et al.
patent: 6455279 (2002-09-01), Ambrosius et al.
patent: 6602688 (2003-08-01), Opper et al.
patent: 154316 (1985-09-01), None
patent: 401384 (1990-12-01), None
patent: 0 731 167 (1996-09-01), None
patent: WO 93/07896 (1993-04-01), None
patent: WO 93/08300 (1993-04-01), None
patent: WO 93/17715 (1993-09-01), None
patent: WO 93/19196 (1993-09-01), None
patent: WO 98/48837 (1998-11-01), None
Arie et al., “Chaperone Function of FkpA, A Heat Shock Prolyl Isomerase, in the Periplasm ofEscherichia coli.” Molecular Microbiology. 39(1):199-210 (2001).
Armour et al., “Recombinant Human IgG Molecules Lacking FCγ Receptor I Binding and Monocyte Triggering Activities.”European Journal of Immunology. 29(8):2613-2624 (Aug. 1999).
Bachmann., “Derivations and Genotypes of Some Mutant Derivatives ofEscherichia coliK-12.”Escherichia coli and Salmonella Typhimurium: Cellular and Molecular Biology. (Washington, DC: American Society for Microbiology.), Chapter 72, 2:1190-1219 (1987).
Barbas III et al., “In Vitro Evolution of a Neutralizing Human Antibody to Human Immunodeficiency Virus Type 1 to Enhance Affinity and Broaden Strain Cross-Reactivity.”Proc. Natl. Acad. Sci. USA91(9):3809-3813 (Apr. 26, 1994).
Bass et al., “Hormone Phage: An Enrichment Method for Variant Proteins with Altered Binding Properties”Proteins: Structure, Function, and Genetics8(4):309-314 (1990).
Bothmann and Pluckthun., “The PeriplasmicEscherichia coliPeptidylprolyl cis, trans-Isomerase FkpA.”J. Bio. Chem.275(22):17100-17105 (Jun. 2000).
Capel et al., “Heterogeneity of HUman IgG Fc Receptors.”Immunomethods. 4:25-34 (1994).
Carter et al., “High LevelEscherichia coliExpression and Production of a Bivalent Humanized Antibody Fragment.”Bio/Technology. 10(2):163-7 (Feb. 1992).
Carter et al., “Humanization of an Anti-p185HER2Antibody For Human Cancer Therapy”Proc. Natl. Acad. Sci. USA89:4285-4289 (May 1992).
Chang et al., “High-Level Secretion of Human Growth Hormone byEscherichia coli.” Gene. 55:189-196 (1987).
Chari et al., “Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs.”Cancer Research. 52:127-131 (Jan. 1992).
Chen et al., “Chaperone Activity of DsbC.”J. Bio. Chem.274(28):19601-19605 (Jul. 1999).
Chothia and Lesk, “Canonical Structures for the Hypervariable Regions of Immunoglobulins”J. Mol. Biol196:901-917 (1987).
Clynes et al., “Fc Receptors Are Required in Passive and Active Immunity to Melanoma.”Proc. Natl. Acad. Sci. USA95(2):652-656 (Jan. 20, 1998).
Cunningham and Wells, “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis”Science244:1081-1085 (1989).
Daeron, M., “Fc Receptor Biology”Annual Review of Immunology15:203-234 (1997).
de Haas et al., “Fcγ Receptors of Phagocytes.”J. of Laboratory Clinical Medicine. 126:330-341 (1995).
Eigenbrot et al., “X-Ray Structures of Fragments From Binding and Nonbinding Versions of a Humanized Anti-CD18 Antibody: Structural Indications of the Key Role of VHResidues 59 to 65”Proteins: Structure, Function, and Genetics18:49-62 (1994).
Fendly, B.M. et al., “Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2
eu Gene Product”Cancer Research50:1550-1558 (Mar. 1, 1990).
Francisco et al., “Agonistic Properties and in Vivo Antitumor Activity of the Anti-CD40 Antibody SGN-14.”Cancer Research. 60:3225-3231 (Jun. 2000).
Friend et al., “Phase I Study of an Engineered Aglycosylated Humanized CD3 Antibody in Renal Transplant Rejection.”Transplantation. 68(11):1632-1637 (Dec. 15, 1999).
Guyer et al., “Immunoglobulin Binding by Mouse Intestinal Epithelial Cell Receptors.”J. Immunol.117(2):587-593 (1976).
Hara et al., “Overproduction of Penicillin-Binding Protein 7 Suppresses Thermosensitive Growth Defect at Low Osmolarity Due to an spr Mutation ofEscherichia coli.”Micro. Drug Resistance. 2(1):63-72 (1996).
Harris., “Therapeutic Monoclonals.”Biochemical Society Transactions23:1035-1038 (1995).
Hawkins et al., “Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation”J. Mol. Biol.226:889-896 (1992).
Henzel et al., “Analysis of Two-Dimensional Gel Proteins by Mass Spectrometry and Microsequencing.”Methods: A Companion to Methods Enzymol.6:239-247 (1994).
Hurle and Gross., “Protein Engineering Techniques for Antibody Humanization.”Curr. Op. Biotech.5:428-433 (1994).
Idusogie et al., “Mapping of the Clq Binding Site on Rituxan, A Chimeric Antibody with a Human IgG1 Pc.”J. Immunol.164:4178-4184 (2000).
Isaacs et al., “A Therapeutic Human IgG4 Monoclonal Antibody that Depletes Target Cells in Humans.”Clin. Exp. Immunol.106:427-433 (1996).
Jackson et al., “In Vitro Antibody Maturation.”J. Immunol.154(7):3310-3319 (1995).
Jones et al., “Replacing the Complementarity-Determining Regions in a Human Antibody with those from a Mouse”Nature321:522-525 (May 29, 1986).
Kikuchi et al., “The Nucleotide Sequence of the Promoter and the Amino-Terminal Region of Alkaline Phosphatase Structural Gene (phoA) ofEscherichia coli.”Nucleic Acids Research. 9(21):5671-5678 (1981).
Kim et al., “Localization of the Site of the Murine IgG1 Molecule That is Involved in Binding to the Murine Intestinal Fc Receptor.”European Journal of Immunology. 24:2429-2434 (1994).
Kipriyanov and Little., “Generation of Recombinant Antibodies.”Mol. Biotech.12:173-201 (1999).
Kostelny et al., “Formation of a Bispecific Antibody by the Use of Leucine Zippers”Journal of Immunology148(5):1547-1553 (1992).
Lindmark et al., “Binding of Immunoglobulins to Protein A and Immunoglobulin Levels in Mammalian Sera.”J. Immunol. Meth.62:1-13 (1983).
Marks et al., “By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling”Bio/Technology10:779-783 (1992).
Matsudaira, P., “Sequence from Picomole Quantities of Proteins Electroblotted onto Polyvinylidene Difluoride Membranes”Journal of Biological Chemistry262(21):10035-10038 (Jul. 25, 1987).
Milstein and Cuello, “Hybrid Hybridomas and Their Use in Immunohistochemistry”Nature305:537-540 (Oct. 1983).
Morrison et al., “Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains.”Proc. Natl. Acad. Sci. USA81:6851-6855 (Nov. 1984).
Picken et al., “Nucleotide Sequence of the Gene for Heat-Stable Enterotoxin II ofEscherichia coli.”Infection and Immunity. 42(1):269-275 (1983).
Pluckthun and Pack., “New Protein Engineering Approaches to Multivalent and Bispecific Antibody Fragments.”Immunotechnology. 3:83-105 (Jun. 1997).
Pluckthun et al., “Producing Ant
Klimowski Laura
Reilly Dorothea
Simmons Laura C.
Yansura Daniel G.
Genentech Inc.
Leffers Gerry
Merchant & Gould P.C.
LandOfFree
Separate-cistron contructs for secretion of aglycosylated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Separate-cistron contructs for secretion of aglycosylated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Separate-cistron contructs for secretion of aglycosylated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3465269